On July 9, 2025, Rhythm Pharmaceuticals, Inc. entered into an underwriting agreement to offer 2,058,824 shares of common stock at $85.00 each, expecting to raise approximately $188.7 million for clinical development and general corporate purposes. The underwriters also exercised a 30-day option for additional shares, with the offering closing expected on July 11, 2025.